Results

Arcadia Biosciences Inc.

08/14/2019 | Press release | Distributed by Public on 08/14/2019 14:11

Arcadia Biosciences Announces Second-Quarter and First-Half 2019 Financial Results and Business Highlights

Arcadia Biosciences Announces Second-Quarter and First-Half 2019 Financial Results and Business Highlightscglife2019-08-14T11:58:42-07:00

- Company launches Archipelago Ventures, a strategic joint venture for superior hemp production and extraction in Hawaii -

DAVIS, Calif. (August 14, 2019) - Arcadia Biosciences, Inc. (Nasdaq: RKDA), a food ingredient company and proven leader in agricultural innovation to improve the quality and nutritional content of crops, today released its financial and business results for the second quarter and first half of 2019.

'We made major progress on several fronts in the second quarter with our wheat, soybean and hemp initiatives,' said Raj Ketkar, president and CEO of Arcadia. 'Most notably, we recently launched Archipelago Ventures, a strategic joint venture with Legacy Ventures Hawaii, which harnesses the islands' unique geographic and climate advantages for growing hemp year-round, gives us access to world class extraction facilities and provides a channel to key international markets for hemp and CBD.'

'Our focus for the rest of 2019 will be on continuing this momentum to achieve first revenues in wheat, soy and hemp by the end of the year, positioning us to significantly scale revenues in 2020.'

Recent Operating and Business Highlights

GoodWheat Advances Toward Sales in 2019
Arcadia scaled up production of its GoodWheat specialty wheat varieties, harvesting winter trials with higher than expected yields. Summer production trials have been planted in key wheat growing areas. The company expects first sales of GoodWheat products by the end of the year.

Arcadia Specialty Genomics Launches Hemp Joint Venture, Advances R&D
Arcadia recently launched a strategic joint venture with Legacy Ventures Hawaii to grow, extract and sell superior sun-grown hemp. The partnership, ArchipelagoTM Ventures, joins Arcadia's extensive genetic expertise and resources with the proven extraction and commercial capabilities of Legacy and its partner Vapen CBD, leveraging Arcadia's existing 10-acre cultivation facility in Hawaii. The result is one vertically integrated supply chain, from seed to sale, enabling Archipelago to deliver superior hemp extract.

The company completed its first harvest in Hawaii and is now expanding production acres and establishing extraction capabilities. First sales of hemp products are expected by the end of the year, with a significant ramp up in 2020.

Arcadia Specialty Genomics has advanced its R&D capabilities as well, in the areas of breeding operations, extraction research, cannabinoid profiling and germplasm acquisition. Most significantly, the company created its first in-house hemp line.

Verdeca HB4® Drought and Herbicide Tolerant Soybeans Receive Key Regulatory Approvals
Verdeca, Arcadia's joint venture with Bioceres Crop Solutions Corp, received two key regulatory approvals for its HB4 drought and herbicide tolerant soybeans. Brazil approved the traits in late May, with a public comment period to follow. The U.S. Department of Agriculture (USDA) recently approved the trait, following the U.S Food and Drug Administration's (FDA's) approval two years ago. Initial sales will commence in Argentina, pending import approval from China, which is now expected in 2020. With the USDA approval, Verdeca will accelerate its evaluation of potential U.S. germplasm partners to carry the HB4 trait.

Arcadia Biosciences, Inc.

Financial Snapshot

(Unaudited)

($ in thousands)

Three Months Ended June 30,

Six Months Ended June 30,

2019

2018

Favorable/
(Unfavorable)

2019

2018

Favorable/
(Unfavorable)

$

%

$

%

Total Revenues

203

436

(233)

(53)%

361

650

(289)

(44)%

Total Operating Expenses

5,184

5,014

(170)

(3)%

9,561

9,067

(494)

(5)%

Loss From Operations

(4,981)

(4,578)

(403)

(9)%

(9,200)

(8,417)

(783)

(9)%

Net Income (Loss)

4,238

(6,669)

10,907

164%

(8,375)

(17,284)

8,909

52%

Revenues

In the second quarter of 2019, revenues were $203,000, compared to revenues of $436,000 in the second quarter of 2018 and first half 2019 revenues were $361,000, compared to $650,000 in the first half of 2018. The decrease for both periods was largely the result of the wind down in government grant and contract research activity. Over the next three to 12 months, as the company transitions to its new focus on health and nutrition quality products, Arcadia expects revenue from government grants and research contracts revenues to be replaced by product and trait revenues from wheat and hemp.

Operating Expenses

Operating expenses in the second quarter of 2019 were $5.2 million, compared to $5.0 million in the second quarter of 2018. Cost of product revenues was $182,000 less in the second quarter of 2019 compared to the second quarter of 2018 due to a write-down of our GLA inventory in the second quarter of 2018. Research and development (R&D) spending increased by $156,000 in the second quarter of 2019, primarily due to higher employee-related expenses and ASG costs. General and administrative (SG&A) costs for the second quarter of 2019 were $196,000 higher than the second quarter in 2018, mainly the result of additional employee-related expenses, as well as increased marketing and public relations activities. In the first half of 2019, operating expenses were $9.6 million, compared to $9.1 million in the first half of 2018. Cost of product revenues decreased by $159,000, or 52 percent, in the first half of 2019 as compared to the first half of 2018, as a result of the GLA inventory write-down in 2018. R&D expenses were $266,000 higher, or 8%, due mainly to the timing of activities in support of Verdeca and SG&A expenses increased by $387,000, or 7 percent, primarily the result of higher employee and recruiting expenses, along with increased consulting, marketing and public relations activities.

Net Income (Loss)

Net income for the second quarter of 2019 was $4.2 million, or income of $0.84 per share, a 164 percent increase from the $6.7 million loss in the second quarter of 2018. Net loss for the first half of 2019 was $8.4 million, or ($1.70) per share, compared to the net loss of $17.3 million for the first half of 2018. The increase for both periods was largely due to the change in the fair value of common stock warrant and common stock adjustment feature liabilities this quarter versus the same quarter last year, partially offset by the $4.0 million initial loss on common stock warrant and common stock adjustment feature liabilities that was recorded in the first quarter of 2018.

Conference Call and Webcast

The company has scheduled a conference call for 4:30 p.m. Eastern (1:30 p.m. Pacific) today, August 14, to discuss second-quarter and first-half financial results and key strategic achievements. Interested participants can join the conference call using the following numbers:

U.S. Toll-Free Dial-In: +1-844-243-4690

International Dial-In: +1-225-283-0138

Passcode: 1488315

A live webcast of the conference call will be available on the 'Investors' section of Arcadia's website at www.arcadiabio.com. Following completion of the call, a recorded replay will be available on the company's investor website.

About Arcadia Biosciences, Inc.

Arcadia Biosciences (Nasdaq: RKDA) develops and markets high-value food ingredients and nutritional oils that help meet consumer demand for a healthier diet. Arcadia's GoodWheat™ branded ingredients deliver health benefits to consumers and enable consumer packaged goods companies to differentiate their brands in the marketplace. The company's agricultural traits are being developed to enable farmers around the world to be more productive and minimize the impact of agriculture on the environment. For more information, visit www.arcadiabio.com

Safe Harbor Statement

'Safe Harbor' statement under the Private Securities Litigation Reform Act of 1995: This press release and the accompanying conference call contain forward-looking statements about the company and its products, including statements relating to components of the company's long-term financial success and ongoing plans; the company's traits, commercial products, and collaborations; and the company's ability to manage the regulatory processes for its traits and commercial products. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the company's and its partners' ability to develop commercial products incorporating its traits and to complete the regulatory review process for such products; the company's compliance with laws and regulations that impact the company's business, and changes to such laws and regulations; and the company's future capital requirements and ability to satisfy its capital needs. Further information regarding these and other factors that could affect the company's financial results is included in filings the company makes with the Securities and Exchange Commission from time to time, including the section entitled 'Risk Factors' and additional information set forth in its Form 10-K for the year ended December 31, 2018. These documents are available on the SEC Filings section of the Investor Relations pages of the company's website at www.arcadiabio.com. All information provided in this release and in the attachments is as of the date hereof, and Arcadia Biosciences, Inc. undertakes no duty to update this information.

Arcadia Biosciences, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

(In thousands, except share data)

June 30, 2019

December 31, 2018

Assets

Current assets:

Cash and cash equivalents

$

14,646

$

11,998

Short-term investments

5,381

9,825

Accounts receivable

125

165

Unbilled revenue

-

3

Inventories - current

839

181

Prepaid expenses and other current assets

1,009

704

Total current assets

22,000

22,876

Property and equipment, net

639

395

Right of use asset

2,051

-

Inventories - noncurrent

649

746

Other noncurrent assets

7

7

Total assets

$

25,346

$

24,024

Liabilities and stockholders' equity

Current liabilities:

Accounts payable and accrued expenses

$

3,265

$

2,645

Amounts due to related parties

19

29

Unearned revenue - current

15

96

Operating lease liability - current

594

-

Other current liabilities

264

284

Total current liabilities

4,157

3,054

Operating lease liability - noncurrent

1,609

-

Common stock warrant liabilities

8,294

5,083

Other noncurrent liabilities

3,000

3,072

Total liabilities

17,060

11,209

Stockholders' equity:

Common stock, $0.001 par value-150,000,000 shares authorized as

of June 30, 2019 and December 31, 2018; 6,266,994

and 4,774,919 shares issued and outstanding as of June 30, 2019 and

December 31, 2018, respectively

47

45

Additional paid-in capital

194,980

191,136

Accumulated deficit

(186,741

)

(178,366

)

Total stockholders' equity

8,286

12,815

Total liabilities and stockholders' equity

$

25,346

$

24,024

Arcadia Biosciences, Inc.

Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

(In thousands, except share and per share data)


Three Months Ended June 30,

Six Months Ended June 30,


2019

2018

2019

2018

Revenues:

Product

$

162

$

188

$

269

$

249

License

-

90

-

90

Contract research and government grants

41

158

92

311

Total revenues

203

436

361

650

Operating expenses:

Cost of product revenues

89

271

148

307

Research and development

1,950

1,794

3,456

3,190

Selling, general and administrative

3,145

2,949

5,957

5,570

Total operating expenses

5,184

5,014

9,561

9,067

Loss from operations

(4,981

)

(4,578

)

(9,200

)

(8,417

)

Other income, net

101

94

221

132

Initial loss on common stock warrant and common stock adjustment feature liabilities

-

-

-

(4,000

)

Change in fair value of common stock warrant and common stock adjustment feature liabilities

9,482

(535

)

987

(2,435

)

Offering costs

(365)

)

(1,639

)

(365)

)

(2,543

)

Net income (loss) before income taxes

4,237

(6,658

)

(8,357

)

(17,263

)

Income tax benefit (provision)

1

(11

)

(18

)

(21

)

Net income (loss)

$

4,238

$

(6,669

)

$

(8,375

)

$

(17,284

)

Net income (loss) per share:

Basic and diluted

$

0.84

$

(2.02

)

$

(1.70

)

$

(6.29

)

Weighted-average number of shares used in per share

calculations:

Basic and diluted

5,054,812

3,307,667

4,916,116

2,746,931

Other comprehensive income, net of tax

Unrealized losses on available-for-sale securities

-

-

-

1

Other comprehensive income

-

-

-

1

Comprehensive income (loss)

$

4,238

$

(6,669

)

$

(8,375

)

$

(17,283

)

Arcadia Biosciences, Inc.

Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)

<_o3a_p>

<_o3a_p>

Six Months Ended June 30,<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

2019<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

2018<_o3a_p>

<_o3a_p>

CASH FLOWS FROM OPERATING ACTIVITIES:<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

Net loss<_o3a_p>

<_o3a_p>

$<_o3a_p>

(8,375<_o3a_p>

)<_o3a_p>

<_o3a_p>

$<_o3a_p>

(17,284<_o3a_p>

)<_o3a_p>

Adjustments to reconcile net loss to cash used in operating activities:<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

Initial loss on common stock warrant and common stock adjustment feature liabilities<_o3a_p>

<_o3a_p>

<_o3a_p>

-<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

4,000<_o3a_p>

<_o3a_p>

Change in fair value of common stock warrant and common stock adjustment feature liabilities<_o3a_p>

<_o3a_p>

<_o3a_p>

(987<_o3a_p>

)<_o3a_p>

<_o3a_p>

<_o3a_p>

2,435<_o3a_p>

<_o3a_p>

Offering costs<_o3a_p>

<_o3a_p>

<_o3a_p>

365<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

2,543<_o3a_p>

<_o3a_p>

Depreciation and amortization<_o3a_p>

<_o3a_p>

<_o3a_p>

77<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

98<_o3a_p>

<_o3a_p>

Lease amortization<_o3a_p>

<_o3a_p>

<_o3a_p>

348<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

-<_o3a_p>

<_o3a_p>

Gain on disposal of equipment<_o3a_p>

<_o3a_p>

<_o3a_p>

-<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

(3<_o3a_p>

)<_o3a_p>

Net amortization of investment premium<_o3a_p>

<_o3a_p>

<_o3a_p>

(82<_o3a_p>

)<_o3a_p>

<_o3a_p>

<_o3a_p>

(27<_o3a_p>

)<_o3a_p>

Stock-based compensation<_o3a_p>

<_o3a_p>

<_o3a_p>

811<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

656<_o3a_p>

<_o3a_p>

Changes in operating assets and liabilities:<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

Accounts receivable<_o3a_p>

<_o3a_p>

<_o3a_p>

40<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

1,051<_o3a_p>

<_o3a_p>

Unbilled revenue<_o3a_p>

<_o3a_p>

<_o3a_p>

3<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

(102<_o3a_p>

)<_o3a_p>

Inventories<_o3a_p>

<_o3a_p>

<_o3a_p>

(561<_o3a_p>

)<_o3a_p>

<_o3a_p>

<_o3a_p>

226<_o3a_p>

<_o3a_p>

Prepaid expenses and other current assets<_o3a_p>

<_o3a_p>

<_o3a_p>

(305<_o3a_p>

)<_o3a_p>

<_o3a_p>

<_o3a_p>

(245<_o3a_p>

)<_o3a_p>

Accounts payable and accrued expenses<_o3a_p>

<_o3a_p>

<_o3a_p>

677<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

(52<_o3a_p>

)<_o3a_p>

Amounts due to related parties<_o3a_p>

<_o3a_p>

<_o3a_p>

(10<_o3a_p>

)<_o3a_p>

<_o3a_p>

<_o3a_p>

(17<_o3a_p>

)<_o3a_p>

Unearned revenue<_o3a_p>

<_o3a_p>

<_o3a_p>

(81<_o3a_p>

)<_o3a_p>

<_o3a_p>

<_o3a_p>

(197<_o3a_p>

)<_o3a_p>

Operating lease payments<_o3a_p>

<_o3a_p>

<_o3a_p>

(349<_o3a_p>

)<_o3a_p>

<_o3a_p>

<_o3a_p>

-<_o3a_p>

<_o3a_p>

Net cash used in operating activities<_o3a_p>

<_o3a_p>

<_o3a_p>

(8,429<_o3a_p>

)<_o3a_p>

<_o3a_p>

<_o3a_p>

(6,918<_o3a_p>

)<_o3a_p>

CASH FLOWS FROM INVESTING ACTIVITIES:<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

Proceeds from sale of property and equipment<_o3a_p>

<_o3a_p>

<_o3a_p>

-<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

9<_o3a_p>

<_o3a_p>

Purchases of property and equipment<_o3a_p>

<_o3a_p>

<_o3a_p>

(315<_o3a_p>

)<_o3a_p>

<_o3a_p>

<_o3a_p>

(68<_o3a_p>

)<_o3a_p>

Purchases of investments<_o3a_p>

<_o3a_p>

<_o3a_p>

(8,623<_o3a_p>

)<_o3a_p>

<_o3a_p>

<_o3a_p>

(18,908<_o3a_p>

)<_o3a_p>

Proceeds from sales and maturities of investments<_o3a_p>

<_o3a_p>

<_o3a_p>

13,150<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

3,900<_o3a_p>

<_o3a_p>

Net cash provided by (used in) investing activities<_o3a_p>

<_o3a_p>

<_o3a_p>

4,212<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

(15,067<_o3a_p>

)<_o3a_p>

CASH FLOWS FROM FINANCING ACTIVITIES:<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

Proceeds from issuance of common stock and warrants from June 2019 Offering<_o3a_p>

<_o3a_p>

<_o3a_p>

7,500<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

-<_o3a_p>

<_o3a_p>

Payments of offering costs relating to June 2019 Offering<_o3a_p>

<_o3a_p>

<_o3a_p>

(619<_o3a_p>

)<_o3a_p>

<_o3a_p>

<_o3a_p>

-<_o3a_p>

<_o3a_p>

Proceeds from issuance of common stock and warrants from Purchase Agreement<_o3a_p>

<_o3a_p>

<_o3a_p>

-<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

10,000<_o3a_p>

<_o3a_p>

Payments of offering costs relating to Purchase Agreement<_o3a_p>

<_o3a_p>

<_o3a_p>

-<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

(1,305<_o3a_p>

)<_o3a_p>

Proceeds from issuance of common stock and warrants from June 2018 Offering<_o3a_p>

<_o3a_p>

<_o3a_p>

-<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

14,000<_o3a_p>

<_o3a_p>

Payments of offering costs relating to June 2018 Offering<_o3a_p>

<_o3a_p>

<_o3a_p>

(24<_o3a_p>

)<_o3a_p>

<_o3a_p>

<_o3a_p>

(1,134<_o3a_p>

)<_o3a_p>

Proceeds from exercise of stock options and ESPP purchases<_o3a_p>

<_o3a_p>

<_o3a_p>

8<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

966<_o3a_p>

<_o3a_p>

Net cash provided by financing activities<_o3a_p>

<_o3a_p>

<_o3a_p>

6,865<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

22,527<_o3a_p>

<_o3a_p>

Net increase in cash and cash equivalents<_o3a_p>

<_o3a_p>

<_o3a_p>

2,648<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

542<_o3a_p>

<_o3a_p>

Cash and cash equivalents - beginning of period<_o3a_p>

<_o3a_p>

<_o3a_p>

11,998<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

9,125<_o3a_p>

<_o3a_p>

Cash and cash equivalents - end of period<_o3a_p>

<_o3a_p>

$<_o3a_p>

14,646<_o3a_p>

<_o3a_p>

<_o3a_p>

$<_o3a_p>

9,667<_o3a_p>

<_o3a_p>

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

Cash paid for income taxes<_o3a_p>

<_o3a_p>

$<_o3a_p>

2<_o3a_p>

<_o3a_p>

<_o3a_p>

$<_o3a_p>

24<_o3a_p>

<_o3a_p>

NONCASH INVESTING AND FINANCING ACTIVITIES:<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

<_o3a_p>

Offering costs in accounts payable and accrued expenses at end of period<_o3a_p>

<_o3a_p>

$<_o3a_p>

22<_o3a_p>

<_o3a_p>

<_o3a_p>

$<_o3a_p>

46<_o3a_p>

<_o3a_p>

Common stock warrants issued to placement agent and included in offering costs related to Purchase Agreement<_o3a_p>

<_o3a_p>

$<_o3a_p>

-<_o3a_p>

<_o3a_p>

<_o3a_p>

$<_o3a_p>

526<_o3a_p>

<_o3a_p>

Common stock warrants issued to placement agent and included in offering costs related to June 2018 Offering<_o3a_p>

<_o3a_p>

$<_o3a_p>

-<_o3a_p>

<_o3a_p>

<_o3a_p>

$<_o3a_p>

239<_o3a_p>

<_o3a_p>

Common stock warrants issued to placement agent and included in offering costs related to June 2019 Offering<_o3a_p>

<_o3a_p>

$<_o3a_p>

86<_o3a_p>

<_o3a_p>

<_o3a_p>

$<_o3a_p>

-<_o3a_p>

<_o3a_p>

Reclassification of common stock adjustment feature liability balance<_o3a_p>

<_o3a_p>

$<_o3a_p>

-<_o3a_p>

<_o3a_p>

<_o3a_p>

$<_o3a_p>

8,378<_o3a_p>

<_o3a_p>

Right of use assets obtained in exchange for new operating lease liabilities<_o3a_p>

<_o3a_p>

$<_o3a_p>

2,328<_o3a_p>

<_o3a_p>

<_o3a_p>

$<_o3a_p>

-<_o3a_p>

<_o3a_p>

Proceeds from sale of fixed assets included in prepaid expenses and other current assets at end of period<_o3a_p>

<_o3a_p>

$<_o3a_p>

-<_o3a_p>

<_o3a_p>

<_o3a_p>

$<_o3a_p>

1<_o3a_p>

<_o3a_p>

Purchases of fixed assets included in accounts payable and accrued expenses<_o3a_p>

<_o3a_p>

$<_o3a_p>

6<_o3a_p>

<_o3a_p>

<_o3a_p>

$<_o3a_p>

-<_o3a_p>

<_o3a_p>